CRISPR Therapeutics CRSP Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.1M-89.1% | $3.51M-90.6% | $38.34M-81.1% | $38.05M-81.2% | $37.68M-86.1% | ||
| $280.9M-8.4% | $284.81M-8.2% | $273.02M-18.2% | $296.28M-13.4% | $306.55M-15.7% | ||
| $71.43M-3.9% | $73.54M+0.8% | $73.27M+2.7% | $73.76M+2.1% | $74.32M+3.6% | ||
| $19.06M-0.5% | $19.48M+1.1% | $18.66M-3.4% | $18.97M-2.8% | $19.16M-2.3% | ||
| $650.5M+27.0% | $668.08M+32.6% | $612.73M+14.5% | $590.52M+6.0% | $512.08M-10.2% | ||
| $650.5M+27.0% | $668.08M+32.6% | $612.73M+14.5% | $590.52M+6.0% | $512.08M-10.2% | ||
| -$646.4M-36.3% | -$664.57M-42.4% | -$574.4M— | -$552.47M— | -$474.4M— | ||
| -15,754.2%-14,495pp | -18,933.6%-17,683pp | -1,498.3%— | -1,451.9%— | -1,259.2%— | ||
| $81.23M-12.4% | $86.61M-16.6% | $89.82M-6.4% | $88.65M-3.1% | $92.72M+10.6% | ||
| -$565.17M-48.1% | -$577.97M-59.4% | -$484.58M— | -$463.82M— | -$381.69M— | ||
| $3.36M-15.3% | $3.63M+1.3% | $3.72M+19.2% | $3.98M+49.7% | $3.97M+73.3% | ||
| -$568.53M-47.4% | -$581.6M-58.8% | -$488.3M— | -$467.8M— | -$385.66M— | ||
| -13,856.5%-12,833pp | -16,569.8%-15,588pp | -1,273.7%— | -1,229.4%— | -1,023.6%— | ||
| -$6.20-37.8% | -$6.50-49.4% | -$5.57— | -$5.41— | -$4.50— | ||
| -$6.20-37.8% | -$6.50-49.4% | -$5.57— | -$5.41— | -$4.50— | ||
| 364.4M+7.0% | 354.2M+5.3% | 348.7M+5.3% | 342.6M+5.3% | 340.5M+6.6% | ||
| 364.4M+7.0% | 354.2M+5.3% | 348.7M+5.3% | 342.6M+5.3% | 340.5M+6.6% | ||
| $201.92M+53.9% | $213.48M+76.9% | $170.19M+30.7% | $124.23M-12.8% | $131.21M-2.8% | ||
| -$574.61M-51.2% | -$578.62M-58.0% | -$493.88M— | -$460.88M— | -$379.97M— | ||
| —— | —— | —— | —— | $6.27M+117% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$3.72M-97.0% | -$3.34M+39.0% | $339K+103% | $551K+104% | -$1.89M+86.6% | ||
| $21K-34.4% | $94K+570% | $6K-95.3% | $110K+3,567% | $32K+10.3% | ||
| -$5.93M-205% | $3.05M+5,860% | -$5.59M-132% | $6.81M+13.0% | $5.66M-27.6% | ||
| $81.23M-12.4% | $86.61M-16.6% | $89.82M-6.4% | $88.65M-3.1% | $92.72M+10.6% | ||
| $1.21M-12.6% | $914K-51.9% | $651K-72.7% | $796K-81.4% | $1.39M-80.6% | ||
| $4.1M-89.1% | $3.51M-90.6% | $38.34M-81.1% | $38.05M-81.2% | $37.68M-86.1% | ||
| $68.61M-21.5% | $72.5M-16.3% | $76.37M-8.0% | $81.31M-0.2% | $87.37M+9.8% | ||
| -$646.4M-36.3% | -$664.57M-42.4% | -$574.4M— | -$552.47M— | -$474.4M— | ||
| -$627.33M-37.8% | -$645.09M-44.2% | -$555.74M— | -$533.5M— | -$455.24M— | ||
| -$627.33M-37.8% | -$645.09M-44.2% | -$555.74M— | -$533.5M— | -$455.24M— | ||
| -15,289.6%-14,081pp | -18,378.7%-17,180pp | -1,449.6%— | -1,402.1%— | -1,208.3%— | ||
| -$646.4M-36.3% | -$664.57M-42.4% | -$574.4M— | -$552.47M— | -$474.4M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is CRISPR Therapeutics's revenue?
- CRISPR Therapeutics (CRSP) generated $4.1M in revenue over the trailing twelve months, down 89.1% year over year.
- Is CRISPR Therapeutics profitable?
- CRISPR Therapeutics is not currently profitable: it reported a net loss of $568.5M over the trailing twelve months, a -13856.5% net margin.
- What is CRISPR Therapeutics's earnings per share?
- CRISPR Therapeutics's diluted EPS over the trailing twelve months is $-6.20.
- Where does CRISPR Therapeutics's income statement data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
